Published in Rheumatol Int on May 12, 2005
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis (2011) 1.96
Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica (2015) 1.94
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum (2009) 1.70
Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am (2010) 1.38
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther (2011) 1.23
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int (2011) 1.17
Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol (2007) 1.12
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol (2008) 0.99
Inflammatory cells and bone loss in rheumatoid arthritis. Arthritis Res Ther (2007) 0.92
Inflammatory response in patients with active and inactive osteoarthritis. Rheumatol Int (2009) 0.90
A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res Ther (2014) 0.85
Citrullinated fibronectin inhibits apoptosis and promotes the secretion of pro-inflammatory cytokines in fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther (2012) 0.84
Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. Rheumatol Int (2008) 0.81
The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. Rheumatol Int (2007) 0.81
Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int (2011) 0.81
Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol (2010) 0.79
Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz) (2015) 0.78
sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. Rheumatol Int (2008) 0.78
Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. Rheumatol Int (2009) 0.76
Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. Dis Markers (2015) 0.75
Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus. Lupus (2016) 0.75
Osteoblasts from osteoarthritis patients show enhanced susceptibility to Ross River virus infection associated with delayed type I interferon responses. Virol J (2014) 0.75
Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. PLoS One (2016) 0.75
Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy. Front Immunol (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med (1968) 27.34
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) (1977) 9.55
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage (1995) 7.18
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem (1997) 4.61
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc (1949) 4.18
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol (1996) 3.63
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum (2000) 3.51
Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum (1984) 3.33
Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet (1987) 2.81
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun (1998) 2.66
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum (2000) 2.61
Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem (2001) 2.02
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) (2001) 2.00
Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. J Rheumatol (1986) 1.98
Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum (1995) 1.93
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) (2003) 1.83
Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem (1999) 1.75
The development of disability in rheumatoid arthritis. Arthritis Rheum (1986) 1.70
Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol (1992) 1.60
High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum (2002) 1.44
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) (2001) 1.35
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum (2001) 1.28
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis (2002) 1.21
Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol (2000) 0.97
The role of osteoprotegerin in arthritis. Arthritis Res Ther (2003) 0.90
The anatomy of the rheumatoid lesion. Br Med Bull (1995) 0.86
Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. Clin Lab (2003) 0.79
Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis (2004) 0.79
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet (2007) 2.50
Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med (1993) 2.20
Recurrence and complications after laparoscopic versus open inguinal hernia repair: results of a prospective randomized multicenter trial. Hernia (2008) 2.18
[Laparoscopic versus conventional appendectomy: a prospective randomized study]. Chirurg (1996) 1.53
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest (2012) 1.43
Pain treatment after thoracotomy: is it a special problem? Ann Thorac Surg (1997) 1.42
In vivo effect of haemodilution with saline on coagulation. Br J Anaesth (2002) 1.40
Pemphigus erythematosus-like rash in a patient on penicillamine. Br Med J (1977) 1.39
Plasma atrial natriuretic factor in cirrhotic patients with ascites. Effect of peritoneovenous shunt implantation. Gastroenterology (1988) 1.39
Big-endothelin release in baboon bacteremia is partially TNF dependent. J Lab Clin Med (1994) 1.39
Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol (1991) 1.31
The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost (2007) 1.31
Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res (2002) 1.27
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int (2011) 1.23
Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy--a porcine model. Br J Anaesth (2006) 1.23
Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone (2003) 1.23
Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia (1988) 1.23
Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab (2012) 1.21
Demonstration of antibodies to collagen and of collagen-anticollagen immune complexes in rheumatoid arthritis synovial fluids. Ann Rheum Dis (1975) 1.19
CADIAG: approaches to computer-assisted medical diagnosis. Comput Biol Med (1985) 1.19
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 1.18
Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth (2005) 1.18
[Autoimmune phenomena in D-penicillamine therapy]. Acta Med Austriaca (1975) 1.17
Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci (1989) 1.11
Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med (1993) 1.11
Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest (2003) 1.06
Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med (2001) 1.06
Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J (2002) 1.05
Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia (1991) 1.03
HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis. J Rheumatol (1984) 1.02
A sensitive immunoradiometric assay for gamma interferon, suitable for its measurement in serum. Clin Chem (1985) 1.01
Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol (2003) 1.00
Seropositive rheumatoid arthritis associated with decreased diffusion capacity of the lung. Ann Rheum Dis (1976) 0.99
Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth (2005) 0.99
Demonstration of anticollagen antibodies in rheumatoid arthritis synovial fluids by 14C-radioimmunoassay. Arthritis Rheum (1978) 0.99
Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol (1992) 0.98
Direct monitoring of molecular recognition processes using fluorescence enhancement at colloid-coated microplates. J Mol Recognit (2001) 0.97
Catalase biosynthesis in yeast: formation of catalase A and catalase T during oxygen adaptation of Saccharomyces cerevisiae. Eur J Biochem (1976) 0.96
Letter: Serum beta2-microglobulin and SLE. Arthritis Rheum (1976) 0.96
Lymphocyte transformation to denatured type I collagen and B lymphocyte alloantigens in rheumatoid arthritis. Arthritis Rheum (1980) 0.94
Normative data of bone mineral density in an unselected adult Austrian population. Eur J Clin Invest (2003) 0.94
Laparoscopic partial posterior fundoplication provides excellent intermediate results in GERD patients with impaired esophageal peristalsis. Surgery (1999) 0.93
Respiratory symptoms in patients with gastroesophageal reflux disease following medical therapy and following antireflux surgery. Am J Surg (1997) 0.93
Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med (2009) 0.92
Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest (1992) 0.91
Decreased serum osteocalcin levels in phenprocoumon-treated patients. J Clin Endocrinol Metab (1988) 0.91
Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol Int (1997) 0.91
Cardiac calcific deposits in patients with primary hyperparathyroidism: preliminary results of a prospective echocardiographic study. Surgery (1990) 0.90
Late complication caused by stone spillage during laparoscopic cholecystectomy. Lancet (1993) 0.90
Virtual computed tomography colonoscopy: artifacts, image quality and radiation dose load in a cadaver study. Eur Radiol (2000) 0.89
Radioimmunoassay of endothelin. Lancet (1989) 0.89
[Initial experiences with substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone]. Monatsschr Kinderheilkd (1990) 0.89
Increased serum osteocalcin levels in patients with paraplegia. Paraplegia (1992) 0.89
Reflux-induced apoptosis of the esophageal mucosa is inhibited in Barrett's epithelium. Am J Surg (1998) 0.88
Peripheral insulin resistance in primary hyperparathyroidism. Metabolism (1983) 0.88
Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol (1998) 0.88
[High dosage vitamin E therapy in patients with activated arthrosis]. Z Rheumatol (1991) 0.87
Totally extraperitoneal inguinal hernioplasty with titanium-coated lightweight polypropylene mesh: early results. Surg Endosc (2005) 0.86
Purification and characterization of a pig intestinal alpha-limit dextrinase. Eur J Biochem (1983) 0.86
Successful parathyroidectomy in primary hyperparathyroidism: a clinical follow-up study of 212 consecutive patients. Surgery (1987) 0.86
Primary hyperparathyroidism and the heart: cardiac abnormalities correlated to clinical and biochemical data. World J Surg (1995) 0.85
The relation of heme to catalase apoprotein synthesis in yeast. J Biol Chem (1980) 0.85
Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop (Belle Mead NJ) (1999) 0.85
Relationship between neopterin and granulocyte elastase plasma levels and the severity of multiple organ failure. Crit Care Med (1989) 0.85
Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis (2000) 0.84
Human atrial natriuretic peptide secretion in precapillary pulmonary hypertension. Clinical study in patients with COPD and interstitial fibrosis. Chest (1988) 0.84
Tomographic examinations of sacroiliac joints in adult patients with rheumatoid arthritis. J Rheumatol (1980) 0.84
Management of hyperparathyroidism in an endemic goiter area. World J Surg (1998) 0.84
Austrian experiences with redo antireflux surgery. Surg Endosc (2005) 0.83
Problems in establishing the medical expert systems CADIAG-1 and CADIAG-2 in rheumatology. J Med Syst (1986) 0.83
Atrial natriuretic peptide concentrations in blood from right atrium in patient with severe right heart failure. Lancet (1985) 0.83
Tubulointerstitial nephritis and uveitis: an immunological disorder? Pediatr Nephrol (1995) 0.83
Relationship of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation (1986) 0.83
Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int (2007) 0.83
[Leukocytic changes under treatment with L-asparaginase]. Wien Med Wochenschr (1971) 0.83
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood (2001) 0.83
Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest (2001) 0.83
Secondary hyperparathyroidism and acute tubular necrosis following renal transplantation. Nephrol Dial Transplant (1993) 0.82
Copper in ankylosing spondylitis and rheumatoid arthritis. Scand J Rheumatol (1978) 0.82
Radioimmunoassay of immunoreactive C-terminal big-endothelin(22-38). Eur J Clin Chem Clin Biochem (1991) 0.82
Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol (1993) 0.82
HLA-B8 in caucasian patients with systemic lupus erythematosus. Scand J Rheumatol (1978) 0.82
Postoperative pain and quality of life after laparoscopic and open inguinal hernia repair: results of a prospective randomized trial. Hernia (2006) 0.81
Alterations of gut neuropeptides in gastroesophageal reflux disease are resolved after antireflux surgery. Am J Surg (2000) 0.81
Living on chronic hemodialysis between dryness and fluid overload. Kidney Int Suppl (1997) 0.81
Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. Rheumatol Int (2006) 0.81
[Pulmonary manifestations in connective tissue diseases (author's transl)]. Prax Klin Pneumol (1979) 0.81
Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int (2001) 0.81
[Serum soluble CD44 isoform variant 5 level in patients with seropositive rheumatoid arthritis treated with cyclosporin A]. Acta Med Austriaca (2000) 0.81
Influence of sex and age on biochemical bone metabolism parameters. Miner Electrolyte Metab (1994) 0.80
Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis. Acta Med Austriaca (1991) 0.80
Morphologic and functional studies to prevent graft-dependent recurrence in renal osteodystrophy. Surgery (1989) 0.80
Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exp Rheumatol (2009) 0.80
Improvement of metabolic syndrome markers through altitude specific hiking vacations. J Endocrinol Invest (2006) 0.80
Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant (1998) 0.80
Selection of patients for laparoscopic antireflux surgery. Dig Dis (2000) 0.80
Soluble CD44 isoform variant-5 (sCD44v5): a new serum marker in rheumatoid arthritis? J Rheumatol (1998) 0.80